Last reviewed · How we verify
LUCANTHONE
LUCANTHONE works by inhibiting DNA-(apurinic or apyrimidinic site) lyase, an enzyme involved in DNA repair.
LUCANTHONE is a small molecule modality targeting DNA-(apurinic or apyrimidinic site) lyase, but its exact mechanism and clinical status are unclear. As a pharmaceutical professional, it is essential to note that LUCANTHONE's development history, commercial status, and approved indications are not publicly available. Further research is necessary to understand its potential therapeutic applications and safety profile. The lack of information on its pharmacokinetic properties, such as half-life and bioavailability, also raises concerns about its clinical use. Overall, LUCANTHONE remains a mysterious entity in the pharmaceutical landscape.
At a glance
| Generic name | LUCANTHONE |
|---|---|
| Target | DNA-(apurinic or apyrimidinic site) lyase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Think of DNA like a long, fragile ladder. When the ladder gets damaged, DNA-(apurinic or apyrimidinic site) lyase helps fix it. LUCANTHONE blocks this enzyme, which can be beneficial in certain types of cancer or other diseases where DNA damage is a problem.
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) (PHASE2)
- Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LUCANTHONE CI brief — competitive landscape report
- LUCANTHONE updates RSS · CI watch RSS